Kodiak Sciences (NASDAQ:KOD) Rating Lowered to “Strong Sell” at Wall Street Zen

Kodiak Sciences (NASDAQ:KOD) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other brokerages have also recently commented on KOD. The Goldman Sachs Group assumed coverage on Kodiak Sciences in a research note on Thursday. They issued a “neutral” rating and a $36.00 price target on the stock. JPMorgan Chase & Co. increased their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kodiak Sciences in a research note on Friday, July 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $58.00 price objective on shares of Kodiak Sciences in a research note on Thursday, September 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Kodiak Sciences presently has an average rating of “Moderate Buy” and an average price target of $56.83.

Kodiak Sciences Price Performance

NASDAQ:KOD opened at $32.35 on Friday. The business has a 50 day moving average of $38.31 and a 200 day moving average of $37.34. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -7.72 and a beta of 2.18. Kodiak Sciences has a 1-year low of $10.94 and a 1-year high of $47.84.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). As a group, sell-side analysts anticipate that Kodiak Sciences will post -3.89 EPS for the current year.

Institutional Trading of Kodiak Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Baker BROS. Advisors LP boosted its position in Kodiak Sciences by 15.1% during the 4th quarter. Baker BROS. Advisors LP now owns 19,919,186 shares of the company’s stock valued at $556,940,000 after acquiring an additional 2,608,696 shares in the last quarter. BlackRock Inc. bought a new position in shares of Kodiak Sciences in the 2nd quarter worth approximately $161,113,000. Jupiter Topco LLC bought a new position in shares of Kodiak Sciences in the 2nd quarter worth approximately $59,507,000. Janus Henderson Group PLC raised its position in shares of Kodiak Sciences by 32.5% in the 1st quarter. Janus Henderson Group PLC now owns 1,325,457 shares of the company’s stock worth $50,540,000 after acquiring an additional 325,457 shares in the last quarter. Finally, ICONIQ Capital LLC purchased a new position in shares of Kodiak Sciences in the 2nd quarter valued at approximately $49,345,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Kodiak announced that it will report topline results on September 28 from the pivotal Phase 3 DAYBREAK study evaluating Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in wet age-related macular degeneration. The readout is the primary near-term catalyst for KOD because successful results could support regulatory filings and materially improve the company’s commercial outlook. Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study
• Positive Sentiment: Market coverage highlights strong investor anticipation ahead of the DAYBREAK results, helping explain the recent surge in Kodiak’s shares. However, the move also raises the risk of a sharp reaction in either direction once the data are released. Kodiak Sciences Shares Surge Ahead of Phase 3 Readout
• Neutral Sentiment: Goldman Sachs initiated coverage with a Neutral rating and a $36 price target, implying moderate upside from the referenced price but signaling limited conviction before the clinical readout.
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, suggesting short covering is unlikely to be a meaningful driver of the recent move.
• Negative Sentiment: Some coverage argues Kodiak looks overvalued after its substantial rally. With the company still precommercial and previously reporting a quarterly EPS loss below consensus, disappointing DAYBREAK data could trigger significant downside. Kodiak Sciences Stock Looks Overvalued After Its 15x Run

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.